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Summary
Three fractions of the low molecular weight heparin CY2l6
(fraxiparin, mean molecular weight [MMW] 5,090), with MMWs
of respectively, 3,090, 4,400 and 7,910 were prepared by gel
permeation chromatography. From CY222 (MMW 3,770) as well
as from CY216 and its three fractions the material with high
affinity to antithrombin III (AT III) was obtained by chromato-
graphy on immobilised AT III. The molecular weight distribution
of each of the ten preparations thus obtained was determined by
high performance liquid chromatography, while the content of
AT III binding material was determined by stoichiometric titra-
tion of AI III, monitored by intrinsic fluorescence enhancement.
We measured the effect of all heparins on the decay of
endogenous thrombin in plasma and on the overall generation of
thrombin in plasma, triggered via the extrinsic or via the intrinsic
pathway. From these data we calculated the time course of
prothrombin conversion, i. e. the course of factor Xa activity as
expressed by prothrombinase activity.
It was found that in platelet-poor plasma the anticoagulant
properties of the heparins are largely dependent on their anti-
thrombin action, which is determined by their content of high
affinity material with a MW of 5,400 or higher. The specific
antithrombin activity of all heparins, when expressed in terms of
material with high affinity to antithrombin III (HAM) with a MW
>5,400 is 13.0 min-'/(pglml) (range 10.-5-15.9). The anticoagu-
lant potency is not influenced by the presence of low-affinity
material and hardly by material with MW <5,400.
In platelet-rich plasma, however, the presence of non-AT III
binding material enhances the inhibition, presumably by
neutralising heparin binding material originating from activated
platelets. The ultra low MW fractions (<3,400) show a similar
activity in PPP and in PRP.
Introduction
Unfractionated heparin (UFH), in concentrations that almost
completely block the appearance of free thrombin triggered via
the intrinsic pathway in platelet-poor plasma (PPP) (-0.1 U/ml),
acts primarily by enhancing the disappearance of thrombin, rather
than by inhibiting prothrombin activation (1, 2). In pathways
where factor VIII figures, the feedback activation of this factor by
thrombin is a rate limiting step (2,3). There, the anti-thrombin
activity of UFH will inhibit the generation of prothrombin
converting activity indirectly by retarding factor VIII activation.
In platelet-rich plasma (PRP) up to 0.4 U/ml of UFH can be
neutralized by platelet factor 4 (pf4) released from activated
platelets (4). Consequently it is not unrealistic to assume that in
situations where activated platelets are present even concentra-
tions of UFH hisher than 0.1 U/ml will still act via thrombin
Correspondence to: Dr. S. Bdguin, University of Limburg, Dept. of
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inactivation rather than via inhibition of prothrombin conversion.
Conversely, the synthetic pentasaccharide (PS) that represents
the antithrombin III (AT III) binding site of heparin, acts on free
factor Xa and is not or hardly affected by pf4 (5, 6). This
substance is therefore essentially different from UFH in that it
blocks the generation of thrombin but does not enhance its
breakdown. Heparin with a chainlength of (18 monosaccharide
units have previously been reported to have similar properties (7).
We have proposed to call those heparins which, like UFH, exert
their action mainly via thrombin inactivation S-type heparirzs and
heparins that act primarily on factor Xa, like PS, P+ype heparins
(1). To our surprise most low molecular weight heparins
(LMWH) acted like S-type- rather than like P-type heparins,
despite the fact that their mean molecular weights suggest that
they should contain considerable amounts of P-type material.
In the present study we attempt to define what fractions of
CY216 and CY222 contain the main active material. To this end
we prepared three fractions of CY216 with medium, low and ultra
low mean molecular weights. From these fractions as well as from
Cy2l6 and CY222 the heparin with high affinity to AT III was
isolated by affinity chromatography. The ten fractions thus
obtained were characterised in terms of molecular weight dis-
tribution by HPLC and in terms of content of high affinity AT III
binding material (HAM) by titration of a known amount of
AT III with the heparin, monitored by the enhancement of the
intrinsic fluorescence of the protein. We measured their effect in
PPP on the decay of endogenous thrombin and on thrombin
generation via the extrinsic and the intrinsic pathway. The effect
on prothrombin conversion velocity was calculated from these
data. The effect of the heparins on thrombin generation in PRP
has been assessed, so as to get an impression of their susceptibility
to neutralisation by activated platelets.
It will be shown that the overall inhibitory activity on thrombin
generation of a heparin in PPP is mainly determined by its content
of HAM with a MW >5,400. In PRP the heparin material with no
affinity for AT III but high affinity for the heparin neutralising
activity (pf4) from the platelets, protects the HAM fraction from
neutralisation.
Materials and Methods
Mateials
The chromogenic substrate for thrombin was H.D-Phe-Pip-Arg-pNA
(52238) from KABI, Sweden. Kaolin was "Kaolin 16ger" provided by
B.L.B. Laboratoires du Bois de Boulogne (Puteaux, France). The low
molecular weight heparins CY216 (4 batches) and CY222 (2 batches)
were supplied and fractionated by Sanofi Recherche, Centre Choay
(Paris, France). One batch of CY21,6 was separated into a medium (M),
low (L) and ultra low (U) molecular weight fractions by gel permeation
chromatography on agarose acrylamide gel ACA 202 (IBF, France).
From the two heparin preparations, as well as from the three fractions, the
material with high affinity to antithrombin III (HAM) was obtained by
affinity chromatography on a sepharose column with covalently bound
ATIII The 4th International Heparin-Standard (4th I.S H ) was
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,.-]he lolec.ular weight distribution profiles of the heparins and thedifferent fractions were determined by gel permeation HpLC on a G2000SW column (7.5 x 300 mm) obtiiiea' from LKB (paris, Francej
connected to a HpLC apparatus composed of a Wateis 510 pump, aWaters 484 UV detector and a VAC 200b Calcul station. The column was
calibrated with a series of narrow_sized heparin fragments prepared bydeaminative cleavage followed by gel filiration. The MWs of these
standards were calculated_ from their precise oligosaccharide composition
as determined by 13C NMR.
Determination of Thrombin Generation in plasma
To 240 p"lof defibrinated.plasma was added 60 pl of 0.05 M Tiis_HCl,0.1.MNaCl, 0.5 mg/ml ovalbumin, pH 7.35, 
"oniuinirrg heparin at rhedesired concentration. Thrombin formation was started by the addition of60 pl of a solution containing 100 mM of CaCI2 and a trigger of
coagulation. For the extdnsic system this was human brain tfr.omToptas_
tin, diluted so as to clot the inhibited, non,defibrinated reaction mixture in70 s (finaldilution 1:240). For the intrinsic system 1 pM phospholipid and0-025 mg taolin (final concentrations) were used. At rntervals, a 10 pl
aliquot of the mixture was sampled into a disposable plastic cuvette
containing 0.465 ml of 0.05 M Tiis_HCl, 0.1 M NaCl, 2b mM EDTA,0 5, mg o,valbumin/rnl, pH 7 .90 and 25 p,l of 5223g (4 mM) prewarmed for
at least 5 min at 37" C. After about 120 s the reaction ln the cuvette was
stopped by adding 300 pr of concentrated acetic acid rhe precise
moments of sampling and stopping were recorded on a personal computerby,means of pushbutton equipped pipettes. The cuvettes were read at405 nm in a double wavelength 1+OS_SOO nm) dedicated instrument
r:p.fl:9 
in our,workshop, reading on the same computer. Amidolytic
acilvrtles (m0D/min) were automatically calculated from the opticaldelsilV 
.an-d the starting and stopping timcs. The observed amidolytic
activity is the sum of thrombin activity and the activity of o,2 macroglobulinbound thrombin (orM-T). Thus at thl end of the reacti,on a stablc level ofactivity is obtained, due to.the o2M_T complex formeO. Assuming apseudo-first order reaction between thrombin and o.2 macroglobulin,
which is likely because of the large excess in plasma of this inhibitor over
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obtained from the National Institute for Biologicar Standards and control
and the synthetic pentasaccharide that represJnts the AT III binding site
of heparin (PS) (5) was supplied by Sanofi Recherche, centre cioay(Paris, France). phospholipidi were 20o/o ptosptratiayf serine and g0%phosphatidyl choline prepared as in ref. g
PIasma
. 
Blood from healthy donors was collected into 0.13 M trisodium citrate;
mne parts of blood to one part of citrate solution. A first centrifugation
was performed at 130 x g, at 15" C for 15 min, and platelet rich piasma(PRP) was taken from the supernatant. A second centritugation was donefor_15 min at 15" C and 2,000 x g to obtain ppp The platelet count of thePRP was adjusted to 300,000 pVpl by dilution with i,pp from the samedonor. Pooled Ppp was prepared from at least 10 donors and the third
centrifugation was done at 4" C, for t h at 20,000 x g, this plasma was
stored at -80" C. It was checked that the clotting lactors and theanuproteases were within the normal range (9). Defibrinated plasma was
ob,tained by mixing an aliquot of plasma witL 1:50 volume oia reptilase
solution, letting a clot form fbr 5 min at 37. C and keeprng the clottedplasma at 0' C for 10 min. The tjbrin fbrmed was discarded by centrifuga_tion (10 min, 2,000 x g, a" C) 
_o-r 
by winding it on a small plastic spatuia.The concentrations of factors II, VII, VIII; IX, X, it ana XII did not
significantly change by the reptilase treatment (9).
Proteins
Reptilase was obtained from..Laboratories Stago (Asnidres, France)
and a solution was made according to the instruciions of the manufac_turer. Soybean trypsin inhibitor (batch No.43 F-g00) was obtained fromSigma (St. Louis, USA). Staphylocoagulase *u, obtained fromI aboratoires Stago (Asnidres, fiance) uid pr"pur"a accordrng to the
rnstructions of the manufacturer. Human train thromboplastin wasprepared according to Owren and Aas (10).
D eterminatio n of M olecular Weight Distribution
Calculation of the Velocity o.f prothrombin Conversion
The Pseudo First Order Rate Constant o.f Thrombin Inhibition in plasma
Antithrombin III Binding
Results
Molecular Weight Distributions and Antithrombin III Binding
Fig. 1 shows the HPLC chromatograms of the heparins used. It
is interesting to note that the molecular weight distribution of the
high affinity fractions of CY222 and CY21'6, when compared to
the total material, had shifted to higher values. Table 1 gives the
weight average- and peak molecular weights obtained from these
chromatograms. Table 1 also gives the results of the fluorescence
experiments in terms of percentage of HAM. There is a general
trend for the percentage of HAM to decrease with the molecular
weight. For the HAM fractions we also determined the percent-
age of material at or above the critical chain length of 1-8 sugar
units that allows an action on thrombin (ACLM) (13-20). On
basis of the ACLM content we can divide the heparins in two
groups, those whose HAM contains a significant amount of higher
MW material (group 1) and those whose HAM contains only
traces of ACLM (group 2). Only the molecules that have both a
high affinity to AT III and a sufficient length can effectively
catalyse thrombin inhibition. We calculated the "/" of such
material in each fraction by multiplying the %ACLM and the
%HAM of the heparin. Because of the differences in molecular
weight distribution between the heparins and their high affinity
fractions, the %ACLM values of the high affinity fractions were
also applied to the heparin from which the HAM material had
been obtained.
Decay of Endogenous Thrombin in Plasma
We found that for all the LMWHs there exists a linear
relationship between the concentration of heparin added to
plasma and the pseudo-first order decay constant of endogenous
thrombin (Fig.2). This linearity holds over the entire concentra-
tion range studied. We define the specific antithrombin activity of
a heparin as the increase in the pseudo first order rate constant of
endogenous thrombin decay per pg/ml of material. This value is
obtained from the slope of lines such as those in Fig.2. From the
specific antithrombin activities of the heparins and their HAM
percentages, we calculated the specific activities of the HAM
contained in the preparations (Thble 1). From this table it can be
seen that, expressed in this way, the specific activity of a heparin
preparation and of the high affinity fraction prepared from it are
not significantly different. There appears to be a clearcut differ-
ence between group 1 and group 2 heparins in that the former
have, on the average, a tenfold higher specific activity when
expressed in terms of HAM.
We also calculated the specific activity per amount of HAM
with a molecular weight >5,400, i. e. above the critical chain
length for interaction with thrombin (ACL-HAM)' In this way we
obtained the specific activity per pg/ml of material with a MW
>5,400 that binds to heparin. Expressed in this way the dif-
ferences between the different heparins in group 1 tend to vanish
and the specific activities scatter around a mean of 13.0 min-r/
(pg/ml), without systematic variation with MW. Unfractionated
heparin still has a roughly two times higher specific activity' Even
when expressed in terms of ACL-HAM, the materials of group 2
do not attain the specific antithrombin activity of those of
group 1. The low amount of ACLM in the heparins of the second
group implies a large experimental error, so we doubt the
signi l icance of this f inding.
Thrombin Generation in Platelet Poor Plasma
The generation of thrombin, measured as amidolytic activity
but compensating for the activity of n2-macroglobulin bound
thrombin, in the absence and presence of different concentrations
of heparins has been determined in the extrinsic and intrinsic
systems. The influence of representative batches of CY216 and
CY222 is shown in Fig.3. In the extrinsic system there is no
significant lag phase in the presence of either heparin. In the
Mol .  Weigh t  (kDa)
0  5  1 0
Mol. Weight (kDa)
Fig. 1 The molecular weight distribution of the heparins studied' Upper
frime: CY222 (Aa) and CY216 (Bb); lower frame: the medium (Mm)-,
low (Ll)- and ultra low (Uu) fractions from CY216' Drawn lines: total
material; dashed lines: high affinity fractions
0 1 2 3
IHEPARTN] (ps/mr)
Fig 2 The pseudo-first order decay constant of endogenous thrombin in
platelet poor plasma. In order of steepness of the curves: L Cy21'6'
medium MW fraction; O CY21'6, total material (4 batches); L Cy222,
totai material (2 batches); L CY276, low MW fraction; a CY21,6,
ultralow MW fraction
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intrinsic system, on the contrary, there is a dose dependent lag
phase for both heparins, albeit less marked wtth CY222 than with
CY216. From these curves we calculated the concentration of
heparin that would cause 25o/o inhibition of the thrombin peak
(IC25). The IC25 value was chosen, rather than the conventional
Table I Molecular properties and specific antithrombin activities
IC50, because the latter value, for practical reasons, can usually
not be obtained for prothrombinase inhibition;it is often so high
that it causes an inhibition of the thrombin peak of more than
85%. This causes thrombin concentrations to be so low as not to
allow sufficiently accurate calculation of prothrombinase activity.
Prep. MMW
(kDa)
PMW
(kDa)
HAM
(7")
ACLM
( % )
Specific activities
total HAM
(min-1/[pg/ml])
ACL-HAM
UFH
Group 1
CY222
cv222-H
cv21,6
CY216-HA
CY216M
CY216M-HA
Group 2
cv216L
CY216LHA
CY216U
CY216U-HA
PENTA
14.50
3.77
5.72
5.09
5 4 7
7.97
7.74
4 4 0
4.62
3 0 9
3.40
r .70
2 9
4 5
4.5
) . 1 )
1 . 6
7 . 7
4 .5
4 .65
2 9
3 0
1 . 7
33
13
100
. A
a /
54
98
39
53
97
8 s 7
0.62
4.08
1.84
4 7 9
8 3 3
12.09
0 0 9
0 2 9
0 0 1
0.20
0.00
25 97
4.71
4.08
1.61
6 4 9
15 43
12.34
0 4 3
0 3 1
0 2 3
0.23
0.00
25.97
r0 46
14 47
12.21,
15.90
72.72
(6 1e)
(4 44)
(3.83)
/ 1  R t \
'7
6
MMW: weight average mean molecular weight; PMW: peak molecular weight; HAM: high affinity material expressed as a''/" of the total material;
ACLM: above critical chain length (MW >5,400) material expressed as a % of the total material. The specific antithrombin activities of the HAM and
the ACL-HAM fractions were calculated from the specific activity of the total material and the HAM, resp ACL-HAM contents
.l50 200
1 5 0
100
50
T|ME (MtN) nME (MtN)
100
nME (MtN) nME (MrN)
Fig 3 The influence of CY216 and CY222 on thrombin generation in platelet poor plasma. Upper frames: CY276; lower frames CY222; Left frames :
extrinsic system; right frames: intrinsic system. CY216 concentrations in order of peak height: control, 0 5 pglml; 1.0 pg/ml; 1.5 pglml. CY222
concentrations in order of peak height: control; 0.5 pg/ml; 10 pg/ml; 1.5 pg/ml; 3 pg/ml
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Table 2 IC25 (in pg/ml) for thrombin peak inhibition Table 3 IC25 (in pg/ml) of
systemsPrep. IC25 thrombin peak
extr lnft. mean
HAM ACLHAM
Prep. Extrinsic system
total HAM
Intrinsic system
total HAMUFH
CY222
CY222-HA
CY216
CY216-I{A
CY21,6M
CY216M-HA
CY21,6L
CY216LHA
CY21,6U
CY216U-HA
PENTA
0.10 0.07
I .35 1 38
0.22 0.17
0.36 0.36
02L  0L7
0.11 0.10
0.09 0 05
3.06 2.38
0-64 0 72
862 7 46
0.85 0.94
0 4 0  0 4 0
0 030
0.069
0 078
0.046
0.075
0.052
0.068
(0 040)
(0.044)
(0.02e)
(0 047)
UFH
CY222
CY222-HA
cY21,6
CY216-HA
CY216M
CY216M.HA
CY21,6L
CY21.6-HA
CY2I6U
CY216U-HA
PENTA
1,.36
0.20
0.36
0 .19
0.10
007
2.72
0 6 8
8.08
0.90
0.40
0.03
0 . 1 8
0.20
0 0 9
0.1,4
0.05
0 0 7
0.57
0.63
0.49
0.79
0 4 0
0.45
5 5 4
0.61
1.45
1.00
0.82
0.27
3.85
0.75
8 9 3
1.09
0.40
0.15
0.72
0.61
0 3 5
0.74
0 4 4
0 2 7
0.81
0 6 9
0.54
0.96
0.40
0.26 0.09
3 32 0.43
0.36 0.36
1.30 0.31
0.38 0 28
0.23 0.13
0.12 0. I2
2.94 0 62
0.81 0 74
7 94 0.48
t .32 r .1,6
0.40 0.40The concentrations at which 25o/o the thrombin peak was inhibited were
determined in the total material. From the known HAM. reso. ACL-
HAM contents it was calculated what concentrations of HAM and ACL-
HAM these concentrations of total material reoresent
The concentrations at which 257" the prothrombinase peak was inhibited
were determined in the total material. From the known HAM content it
was calculated what concentrations of HAM material these concentrations
of total material reoresent
1 0 0
1 0
T|ME (MrN)
1 0 0
0 5 1 0 1 5 2 0
IME (MtN)
Fig.4 Influence of CY2l6 and CY222 on thrombin activity in pRp.
Thigger: Recalcification in the presence of highly diluted thromboplastin
(1:2,400). Upper frame: total materiai; O control; O 3 pg/ml Cy222;
A 1 pglml CY216. Lower frame: high affinity ftactions; O control;
O 0 45 pg/ml CY222; A 0.5 pg/ml Cy216
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Table 4 Inhibition of the
plasma
peak of thrombin generation in platelet_rich
0.20
3.00
0.45
i .00
0.50
0.20
0.15
6.00
1.50
20.00
2.00
1.00
goncentrations of heparin where sought thu, inhib;;;;bi;l;_uri;
l1-a^ll.,T-Ol::J0%, then the_effect of tr,ri 
""".""tr"uon on thrombin
instrinsic and the extrinsic system (mean ratio 1.0, range 0.g_1.3)(Table 3).
Influence on Thrombin Generation in platelet Rich plasma
Prep Conc.
(pglrnl)
Inhibition (%)
PPP PRP
UFH
CY222
CY222.HA
CY216
CY216-HA
CY216M
CY216M-HA
CY276L
CY216L.HA
CY276U
CY216U-HA
PENTA
0
76
0
27
9
6
0
22
2
54
51
53
55
55
52
56
54
45
46
49
52
5l
55
49
generation in pRp was assessed
t 3
Discussion
monosaccharide units (%ACL_it
gated in how far these rwo propertr
a heparin on thrombin generalion in plasma.
We determined the t HAM by fl;;;;ce titration and the%ACLll from the elution profiles.irfr" ffpiC chromatograms.The %ACLM of the high utrnity r.u.tio^ *"u, used to estimatethe ACL-HAM conten-r of the corresponOingi"purins. We rhenexpressed the observed activities of each hep-arin in terms of theHAM and ACL-HAM tha t  i t  conra in . .  
' - ' * '
- 
It isinteresting to observe (Table 1, Fig. 1) that the mean MWof the high affinity fractrons ten
original material. This is a los
probabil i ty of severing rhe pe"r
longed depolymerisation. It has
two heparins such as Cy2I6 and. I
as quite different on the basis of t
the active HAM that they contain.
It is well documented that Ca2+ ion concentration and the
ave rmportant effects on the
tII and activated clotting factors
erelore attempted to deviate as
zo conditions by working in aI concentrations. We meisured
td pRp and determined the
rmbin breakdown. From these
conversron. 
the heparins on prothrombin
I  t t ,
E
N
- q
5  l o
Anti th rombi n specif ic act ivi ty (min-1/(pglm l))
fliit,ilj'lT:il?i#"',1i" activitv and IC25 (see text); o: g tvps
Thrombin inhibition values i
system were not signif icantly d
tne lwo values for further cal
dif lerences between a heparin a
disappear when we express th
differences between all the hep
IC25 on basis of the ACLHAI
unfractionated heparin, 50 to 6group and 30 to 50 ng/ml for those of the second group.
Influence on prothrombinase Activity in plasma
e calculated from curves such as
as lmportant as those i, th".".;J;:"J:,:T [.T;.Jr#r.,r-,f:first group (mean ratio ?f-_,!_:^".!"ir j;; ;-.i, iange r.r_:.6, nosystematic variation with-MMW). no, tfr" fr"purts of the secondgroup there was no difference between tli inliUltlons in the
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Thrombin Breakdown
From Table 1 it is immediately obvious that the heparins come
in two kinds: those with a high specific activity in thrombin decay
and those with a low one. This is especially clear when the specific
activity is expressed in terms of high affinity material. The first
group, that of the S heparins (1), comprises CY216, its medium
molecular weight fraction and CY222. To the second group, the P
heparins, belong to the low and ultra-low molecular weight
fractions of CY276. The specific decay constant, when calculated
per pg of HAM, does not differ significantly between a heparin
and its corresponding high affinity fraction, indicating that the low
affinity material present does not influence the thrombin decay.
Calculated per pg of ACLHAM, the specific activity does not
vary much between the LMWHs of the S-type group (mean 13.0,
range 10.7-15.9). For the P-type LMWHs, the small amount of
ACLM, which is necessarily just above the lower limit that allows
antithrombin activity, seems to have a low specific activity,
whereas that of UFH seems to be some 2 times higher than that of
the LMWHs. This is suggestive of variation of the molar
antithrombin specific activity with the chain length. The dispersity
of the molecular weight distributions and the large experimental
error in the P group, due to the low specific activities and low
percentages of higher MW material there, does not allow this
hypothesis to be tested with the present material.
Pr othrombin Conversion
Both in the intrinsic and in the extrinsic system, large
differences are found between the IC25 values for the activation
of prothrombin when the inhibitory concentrations are expressed
in terms of total material but when they are calculated in terms of
HAM, the differences are much less pronounced (Thble 3). In the
extrinsic system we find no significant difference between the
HAM-IC25 values in the S and the P groups. The mean IC25 is
0.56 pglmf of HAM (range 0.27-0.96). Within this range the
variation does not seem to depend on the MMW of the fraction.
For the S-type heparins the IC25 for intrinsically generated
prothrombinase is about two times lower than for extrinsic
prothrombinase (mean 0.26, range 0.12-0.43). This is not found
for the P-type group (mean 0.75, range 0.48-1.16). This differ-
ence is probably explained by the fact that, in the intrinsic system,
those heparins that have a significant antithrombin activity inhibit
the generation of prothrombinase indirectly by inhibiting the
thrombin mediated factor VIII activation, which may entail
factor IXa inhibition (1,2,25-27). In situations where inhibition
of thrombin mediated feedback, although present, is not rate
limiting, i. e. for all heparins in the extrinsic system and for the P-
type heparins in the intrinsic system, the HAM-1C25 of prothrom-
binase is similar. This indicates that all LMWHs have roughly the
same antiprothrombinase effect unless their capacity to inhibit
thrombin causes secondary inhibitory effects on the generation of
prothrombinase activities.
Inhibition of Free Thrombin Formed in Plasma
The HAM-IC25 values for thrombin inhibition in the S-rype
group show a mean of 0.12 pglml (range 0.05-0.20), which is
about 5 times lower than those for prothrombinase. This shows
that the antithrombin activity of the S-type heparins overshadows
their antiprothrombinase activity. In the P-type group the HAM-
IC25 for thrombin (mean 0.62 pg/ml, range 0.49-0.79) is not
different from that of prothrombinase inhibition (0.75 pg/ml,
range 0.54-0.96), which is a normal consequence of the fact that,
in the absence of anti-thrombin activity, the inhibition of the
thrombin peak results from inhibition of prothrombinase activity.
Fig.6 shows that the inhibitory potency of the S-type heparins,
expressed as the inverse of their lC25 for thrombin, is directly
proportional to their specific anti-thrombin activity. Antithrom-
bin activity results in immediate, proportional inhibition of the
thrombin peak, whereas the anti-factor Xa activity does not.
This apparent paradox is readily explained from the nature of
the prothrombin converting enzyme. The levels of thrombin
obtained in clotting plasma result from the combined action of
heparin on prothrombin conversion and on thrombin decay.
An increase in antithrombin activity under the influence of
heparin will lead to a proportional decrease in the thrombin
concentration. A decrease in the prothrombinase activity will
cause a proportional decrease in prothrombin conversion. But
prothrombinase activity is not proportional to the amount of
factor Xa present, so that factor Xa inactivation does zol lead to a
proportional decrease in prothrombinase activity.
Prothrombinase is a tripartite complex of factors Xa and Va
and phospholipid arising from simple chemical equilibria (28).
From B6guin (2) we know that_the normal peak prothrombinase
activity is about 200 nM min-'; from the kinetic constants for
prothrombin conversion given by Rosing et al. (8), we calculate
that under the conditions of our experiments this reaction velocity
is obtained by 0.3 nM or less of prothrombinase complex, i. e. at
slightly more than 0.3 nM of the rate limiting prothrombinase
component. Pieters and Lindhout (29) found that in clotting
plasma, under our conditions, factor Va is the limiting prothrom-
binase component and that factor Xa is in large excess (-10 nM)
over the limiting factor Va (-0.3 nM) (29). The binding constant
of factor Xa to phospholipid bound factor Va is 0.1 nM (30). This
means that at 0.3 nM factor Va and 10 nM factor Xa, -0.297 nM
prothrombinase is formed while 1 nM factor Xa leads to the
formation of -0.273 nM prothrombinase. Inhibition of the fac-
tor Xa peak of -90% will cause -87" inhibition of prothrom-
binase.
As early as 1970 Yin proposed that it was a normal consequ-
ence of the clotting cascade that factor Xa inhibition would lead
as readily to inhibition of thrombin generation as inhibition of
thrombin would (31). This idea is at the basis of much of the later
work on the antithrombotic action of heparins. Now that we know
the details of the enzymology of prothrombinase it is readily seen
why this is not true. It has been suggested previously that tests
based on the inhibition of prothrombin activation and/or on the
catalysis of thrombin inhibition provide a useful basis for assign-
ing in vivo potency to both unfractionated and LMW heparins
(32). Our results suggest that thrombin inhibition rather than
prothrombin conversion should be the yardstick for the potency
of heparins.
In terms of ACL-HAM the IC25 value for thrombin inhibition
is very similar for all S-type heparins: 64 nglml (range 46-78). For
unfractionated heparin it is even lower: 30 ng/ml, which suggests
that, as was seen with the thrombin decay constants, UFH is
about 2 times more active than LMWHs.
The inhibition of thrombin generation in clotting plasma by
LMWHs is thus brought about by their antithrombin activity as
soon as they possess that activity. At a MW <5,400, having anti
Xa activity only, heparins will still inhibit thrombin formation in
plasma, but at about 5 fold higher concentrations. This explains
why the amount of HAM with a MW <5,400 in a LMWH
preparation has to be fairly high before it starts to act via
inhibition of prothrombin conversion (33). If we assume that a
decrease of the amount of free thrombin arising in activated
plasma is the lever of the antithrombotic action of heparins (and
probably of many other drugs), then it also explains why the
synthetic pentasaccharide and other P-heparins need to be given
in high doses in order to have an antithrombotic effect (34). It is
clear that a LMW heparin cannot be regarded as a homogeneous
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substance. Its different components have different in vitro
activities and will in all probability also have different phar-
macokinetic properties, the lower MW molecules having a longer
half life time. This makes that the effect observed in vivo after
injection may progressively shift from the S-type to the P-type.
Platelet Rich Plasma
In platelet rich plasma the inhibition by LMWHs is systemati-
cally more important than that brought about by an amount of
UFH which is equivalent in PPP (4). This must be attributed to
the fact that much more pf4 binding molecules are present in a
dose of LMWH than in an otherwise equivalent dose of UFH, so
that LMWH preparations can neutralize the pf4 released by the
activated platelets of PRP (35 , 36, cf also the accompanying paper
by Schoen et al.) .
The experiments reported in Figs.4 and 5 and in Table 4 show
that the LMWHs retain an inhibitory activity in the presence of
platelets under conditions where an amount of UFH, which in
PPP is equipotent, does not. This is evidently a function of the
non-AT III binding material present, because the effect is sys-
tematically less important in the HAM preparations than in the
corresponding original fractions. There is also an effect of MW
On the one hand the medium MW preparation is neutralised
fairly efficiently, while on the other hand the ultralow MW
heparins escape neutralisation almost entirely, even if they
contain ahigh % of HAM.
Since we may consider PRP to be a better model of the
situation in vivo than PPP is, this suggests that the clinical efficacy
of a LMWH may be determined, at least in part, by the amount of
its material that reacts with pf4 but not with AT III on the one
hand, and by the amount that binds to AT III but not so well to
pf4 on the other. The former will neutralise pf4 and in this way
protect anticoagulant heparin. The latter will be to a certain
degree immune to pf4 action.
Conclusions
Our observations lead to the following hypothesis:
The most active part of LMWHs is to be found in the AT III
binding fraction with a molecular weight higher than 5,400. The
effect of these fractions on the biochemical processes in blood
coagulation is not essentially different from that of UFH, but their
pharmacodynamics are more favourable and they are less readily
neutralised by (products from) activated platelets.
It follows from this hypothesis that it should be worthwile to
investigate, in animal and human studies, the antithrombotic
effect of a LMWH compared to its high affinity >5,400 MW
fraction, spiked with different amounts of inactive, but platelet
factor 4 binding material.
Besides the AT III affinity and the length of more than 18
sugar units, other properties of heparin may determine its
activity. Anti-factor Xa and antithrombin activity have been
reported to increase gradually with MW and it is not inconceiv-
able that chemical composition outside the pentasaccharide
region may modify the properties of a heparin. The present data
however do not allow conclusions on this matter.
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